The Company's Board of Director's resolution on
ex-rights date
Date of events
2022/08/12
To which item it meets
paragraph 14
Statement
1.Date of the resolution by the board of directors or
shareholders' meeting, or of the decision by the company:2022/08/12
2.Type (ex-rights or ex-dividend) (please write "Ex-rights",
"Ex-dividend", or "Ex-rights and dividend"):Ex-rights
3.Type and monetary amount of dividend distribution:
Stock dividend:Each share is entitle to 1 stock dividend,
total amounted to NTD 68,522,280
4.Ex-rights (Ex-dividend) date:2022/08/30
5.Last date before book closure:2022/08/31
6.Book closure starting date:2022/09/01
7.Book closure ending date:2022/09/05
8.Ex-rights (Ex-dividend) record date:2022/09/05
9.Deadline for applying the conversion of the debt voucher:NA
10.The closure period for the conversion of the debt voucher will
start from the date:NA
11.The closure period for the conversion of the debt voucher will
end on the date:NA
12.Payment date of cash dividend distribution:NA
13.Any other matters that need to be specified:
(1)The Company's issuing new shares through capital surplus
has been approved by Financial Supervisory Commission on
2022/08/04.
(2)Original dividend type and amount:Stock dividend and amounted
to TWD 68,522,280 (NTD 1 per share, every thousand share is
eligible for 100 share).
(3)Revised dividend type and amount:Stock dividend and amounted
to TWD 68,522,280 (NTD 1.004294344 per share, every thousand
share is eligible for 100.4294344 share).
(4)The share changes is due to the employee exercise employee
stock option and treasury stock, which affects the dividend
rate, the Board of Directors is authorized to take necessary
action.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Bora Pharmaceuticals Co. Ltd. published this content on 12 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 August 2022 12:14:13 UTC.
Bora Pharmaceuticals Co Ltd is a Taiwan-based company principally engaged in the agency and sales of western medicines, as well as the research, development, manufacture and sales of new drugs and health products. The Company's main products are categorized into prescription drugs and health care products, including central nervous drugs, cardiovascular drugs, antibiotics, antiviral agents, ophthalmic drugs, gastrointestinal drugs, foam ingots and health care products. In addition, the Company has biopharmaceutical technologies related to the development of cell lines for the production of protein drugs, the development and analysis of upstream and downstream processes, as well as the establishment of quality control and testing specifications and the creation of cell banks.
BORA PHARMACEUTICALS CO., LTD. 
